News & Events about Maxcyte Inc.
Curamys to use MaxCytes Flow Electroporation technology and ExPERT platform to help advance its cell fusion technology.ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...
Ticker Report
3 months ago
MaxCyte, Inc. (NASDAQ:MXCT Get Rating) EVP Thomas M. Ross sold 4,282 shares of the businesss stock in a transaction that occurred on Tuesday, October 11th. The stock was sold at an average price of $6.51, for a total transaction of $27,875.82. The transaction was disclosed in a filing...
Ticker Report
5 months ago
MaxCyte (NASDAQ:MXCT Get Rating) had its target price raised by BTIG Research from $10.00 to $11.00 in a report issued on Sunday, The Fly reports. MaxCyte Price Performance Shares of MXCT opened at $5.87 on Friday. The stock has a market capitalization of $596.55 million and a P/E ratio of -...
Globe Newswire
6 months ago
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, ...
Globe Newswire
9 months ago
GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, ...